RET
Other names: RET fusion, RET rearrangement
RET fusion is rare, but when found it can open discussion of a specific targeted therapy category.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Plain explanation
RET fusion occurs when the RET gene fuses with another gene. This is discovered through molecular examination and cannot be predicted from symptoms alone.
Clinical meaning
RET fusion in non-small-cell lung cancer is discussed in the category of RET inhibitors. These findings are usually part of a broader sequencing panel.
Testing methods
- Next-generation sequencing (NGS)
A test that reads many genes from one tumour sample to find actionable changes.
- FISH (fluorescence in situ hybridisation)
A test that detects changes in the number or arrangement of genetic material in tumour cells.
- Liquid biopsy (ctDNA)
A blood test that looks for tumour genetic material to supplement or partly replace tissue testing.
A negative result does not always mean the marker is absent
Test sensitivity differs by sample type and method. Results need to be read together with the pathology report and clinical condition.
What needs verification
- The name of the laboratory-reported fusion gene pair.
- Does the panel also check other relevant markers at the same time?
- Clinical conditions and therapy history.
- Access and financing of medicines at selected facilities.
Related drugs
- Selpercatinib
Selective RET inhibitor
- Pralsetinib
Selective RET inhibitor
A link here means the marker is often part of considering a drug category, not a recommendation to use it.
Clinical trials
Studies mentioning this marker
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT01639508Phase 2Combination regimen
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Lung Cancer | biomarker: ROS1, MET, RET, NTRK
United States7 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker ROS1.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT01639508Not verified
Check options based on your result
Share the RET result you have so we can explain which categories to discuss with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Lung Cancer
Cancer type
Reason: Related through a biomarker
- Newly diagnosed lung cancer
Decision situation
Reason: Related through a biomarker
- Metastatic lung cancer
Decision situation
Reason: Related through a biomarker
- RET fusion
Molecular alteration
Reason: Related through a biomarker
- Targeted therapy
Treatment category
Reason: Related through a biomarker
- Pralsetinib
Drug
Reason: Targets this marker
To check
- FISH (fluorescence in situ hybridisation)
Diagnostic test
Reason: Diperiksa melalui
- Liquid biopsy (ctDNA)
Diagnostic test
Reason: Diperiksa melalui
- Next-generation sequencing (NGS)
Diagnostic test
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.